TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19248858

Group type: EXPERIMENTAL
Intervention: Beverage (apple juice)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Solid food (apple)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Semisolid food (apple sauce)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Test day energy intake
Number of subjects: 40
Study: 17201541

Group type: EXPERIMENTAL
Intervention: Threat of social exclusion
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Fear of negative evaluation (low)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Fear of negative evaluation (high)
Number of subjects: 6
Study: 15545544

Group type: EXPERIMENTAL
Intervention: 5 U of botulinum exotoxin A in 0.25 mL of preserved saline (2 U/0.1 mL)
Number of subjects: 10

Group type: COMPARATOR
Intervention: 5 U of botulinum exotoxin A in 0.05 mL of preserved saline (2 U/0.02 mL)
Number of subjects: 10
Study: 11319508

Group type: EXPERIMENTAL
Intervention: Estriol treatment per vaginam
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (no estriol treatment)
Number of subjects: 20

Group type: COMPARATOR
Intervention: Both groups (treated and control)
Number of subjects: 20
Study: 9151148

Group type: EXPERIMENTAL
Intervention: Biosulfane membrane (highly asymmetric hydrophobic polysulfone)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: PS600 membrane (moderately asymmetric and hydrophobic polysulfone)
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: AN69HF membrane (Polyacylonitrile)
Number of subjects: 6
Study: 8043059

Group type: EXPERIMENTAL
Intervention: Preoperative chemotherapy plus surgery
Number of subjects: 60

Group type: COMPARATOR
Intervention: Surgery alone
Number of subjects: 60
Study: 3306494

Group type: EXPERIMENTAL
Intervention: labetalol (20‐80 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: hydralazine (5 mg)
Number of subjects: 60

Group type: COMPARATOR
Intervention: hydralazine
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: labetalol
Number of subjects: 60
Study: 31337404

Group type: EXPERIMENTAL
Intervention: 4AT (scores 0-12; prespecified score of > 3 considered positive)
Number of subjects: 785

Group type: COMPARATOR
Intervention: CAM (Confusion Assessment Method; scored positive or negative)
Number of subjects: 785
Study: 26922436

Group type: EXPERIMENTAL
Intervention: Punica granatum var pleniflora mouthwash
Number of subjects: 80

Group type: COMPARATOR
Intervention: Chlorhexidine 0.2%
Number of subjects: 80
Study: 25924855

Group type: EXPERIMENTAL
Intervention: Procera crowns
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: IPS e.max Press crowns
Number of subjects: 27

Group type: COMPARATOR
Intervention: Crown therapy (both types)
Number of subjects: 27
Study: 23590389

Group type: EXPERIMENTAL
Intervention: Procalcitonin-guided therapy
Number of subjects: 1816

Group type: COMPARATOR
Intervention: Standard of care
Number of subjects: 1816
Study: 21762476

Group type: EXPERIMENTAL
Intervention: Plate fixation
Number of subjects: 120

Group type: COMPARATOR
Intervention: Elastic Stable Intramedullary Nailing (ESIN) with a Titanium Elastic Nail (TEN)
Number of subjects: 120
Study: 19863317

Group type: EXPERIMENTAL
Intervention: Ecologically produced wine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditionally produced wine 1
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditionally produced wine 2
Number of subjects: 0
Study: 17108420

Group type: EXPERIMENTAL
Intervention: Same-side loaded condition (15% body load)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Cross-body loaded condition (15% body load)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Unloaded condition
Number of subjects: 21
Study: 15611457

Group type: EXPERIMENTAL
Intervention: Low‐pressure, nonsequential pneumatic compression sleeves
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control group (no sleeves used)
Number of subjects: 45
Study: 12162602

Group type: EXPERIMENTAL
Intervention: Individualized calcium (Ca) and phosphorus (P) supplementation adjusted to achieve urinary excretion of > or = 1.2 mmol/L Ca and > or = 0.4 mmol/L P.
Number of subjects: 20
Study: 9583766

Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA) with pethidine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Staff-controlled analgesia with pethidine
Number of subjects: 20
Study: 7644079

Group type: EXPERIMENTAL
Intervention: Oral sumatriptan 25 mg
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Oral sumatriptan 50 mg
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Oral sumatriptan 100 mg
Number of subjects: 187

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 187

Group type: EXPERIMENTAL
Intervention: Oral sumatriptan
Number of subjects: 187
Study: 2787310

Group type: EXPERIMENTAL
Intervention: Lung hyperinflation at tidal volume 12 cc/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lung hyperinflation at tidal volume 14 cc/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lung hyperinflation at tidal volume 16 cc/kg
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: Lung hyperinflation at tidal volume 18 cc/kg
Number of subjects: 8
Study: 342359

Group type: EXPERIMENTAL
Intervention: Carbenoxolone capsules (Duogastrone, 50 mg four times a day for six weeks)
Number of subjects: 86

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86

Group type: EXPERIMENTAL
Intervention: Carbenoxolone capsules
Number of subjects: 86
Study: 31866104

Group type: EXPERIMENTAL
Intervention: Behaviour therapy for drug abusers (120 days treatment)
Number of subjects: 640

Group type: COMPARATOR
Intervention: Behaviour therapy for alcohol abusers (90 days treatment)
Number of subjects: 640

Group type: EXPERIMENTAL
Intervention: Behaviour therapy for both groups
Number of subjects: 640
Study: 30756167

Group type: EXPERIMENTAL
Intervention: Intermittent normobaric hypoxia (IH) with FiO2 at 13.5% for 180 minutes
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: Intermittent normobaric hypoxia (IH) with individually adjusted FiO2 to achieve 80% oxygen saturation for 180 minutes
Number of subjects: 123

Group type: COMPARATOR
Intervention: Control group (normoxic exposure)
Number of subjects: 123
Study: 28646811

Group type: EXPERIMENTAL
Intervention: Tui na treatment (2 times/week for 10 weeks, 15 min/session)
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: Tui na treatment
Number of subjects: 31
Study: 26110296

Group type: EXPERIMENTAL
Intervention: co‐trimoxazole (960 mg twice a day)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: norfloxacin (400 mg twice a day)
Number of subjects: 175

Group type: EXPERIMENTAL
Intervention: levofloxacin (250 mg once a day)
Number of subjects: 175
Study: 22573730

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study: 21991740

Group type: EXPERIMENTAL
Intervention: Intubating Laryngeal Mask Airway (ILMA)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 80
Study: 18926729

Group type: EXPERIMENTAL
Intervention: Celecoxib 200mg b.d.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indomethacin 50mg b.d.
Number of subjects: 0

Group type: COMPARATOR
Intervention: No treatment (Control)
Number of subjects: 0
Study: 17114880

Group type: EXPERIMENTAL
Intervention: Clopidogrel 600 mg loading dose in addition to standard acetylsalicylic acid/heparin treatment
Number of subjects: 654
Study: 15119913

Group type: EXPERIMENTAL
Intervention: Supportive clinical environment treatment program
Number of subjects: 175
Study: 10850391

Group type: EXPERIMENTAL
Intervention: HPLC method for quantification of codeine and its metabolites
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: CYP2D6 phenotyping using codeine, debrisoquine, and dextromethorphan
Number of subjects: 11
Study: 8756971

Group type: EXPERIMENTAL
Intervention: Stay at the Dead Sea (1 week)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stay at the Dead Sea (3 weeks)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Stay at the Dead Sea
Number of subjects: 0
Study: 1581278

Group type: EXPERIMENTAL
Intervention: Standard progesterone regimen
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: High progesterone regimen
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Low progesterone regimen
Number of subjects: 14
Study: 3981625

Group type: EXPERIMENTAL
Intervention: Diazepam (10 mg orally)
Number of subjects: 0
Study: 29958049

Group type: EXPERIMENTAL
Intervention: 1 g oral NAC
Number of subjects: 17

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 17
Study: 27863843

Group type: EXPERIMENTAL
Intervention: Intravitreal bevacizumab
Number of subjects: 362

Group type: COMPARATOR
Intervention: Intravitreal aflibercept
Number of subjects: 362
Study: 26119263

Group type: EXPERIMENTAL
Intervention: Verbal-linguistic mentation
Number of subjects: 138

Group type: COMPARATOR
Intervention: Mental imagery
Number of subjects: 138

Group type: COMPARATOR
Intervention: Low trait ruminators (both mentation types)
Number of subjects: 138
Study: 24054756

Group type: EXPERIMENTAL
Intervention: 0.2% isosorbide 5 mononitrate (Group A)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 2% diltiazem (Group B)
Number of subjects: 55

Group type: EXPERIMENTAL
Intervention: 2% diltiazem + 0.2% isosorbide 5 mononitrate (Group C)
Number of subjects: 55
Study: 21711205

Group type: EXPERIMENTAL
Intervention: CCH1
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 19250773

Group type: EXPERIMENTAL
Intervention: Motivation to quit smoking at T0 (4-6 weeks postpartum)
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: Motivation to quit smoking at T1 (6 months postpartum)
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: Motivation to quit smoking at T2 (12 months postpartum)
Number of subjects: 871

Group type: EXPERIMENTAL
Intervention: Relapse into earlier stages of motivation to quit smoking
Number of subjects: 871
Study: 16914594

Group type: EXPERIMENTAL
Intervention: recombinant human TSH (rhTSH) preparation
Number of subjects: 100000

Group type: COMPARATOR
Intervention: hypothyroid preparation
Number of subjects: 100000
Study: 15273269

Group type: EXPERIMENTAL
Intervention: Asthma screening questionnaire administered to parents
Number of subjects: 3067
Study: 11093918

Group type: EXPERIMENTAL
Intervention: H(2)-receptor antagonists (cimetidine or ranitidine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dehydration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: H(1)-receptor antagonist (mepyramine)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: H(1)- and H(2)-receptor blockade
Number of subjects: 0
Study: 9262979

Group type: EXPERIMENTAL
Intervention: In-house 13C-urea breath test
Number of subjects: 110

Group type: COMPARATOR
Intervention: Commercial 13C-urea breath test
Number of subjects: 110
Study: 8471592

Group type: EXPERIMENTAL
Intervention: Interferon-gamma at 0.1 mg/m2
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Interferon-gamma at 0.25 mg/m2
Number of subjects: 15

Group type: COMPARATOR
Intervention: Interferon-gamma at 0.01 mg/m2
Number of subjects: 15
Study: 3519353

Group type: EXPERIMENTAL
Intervention: Methylergometrin (0.125 mg, 3 times a day for 4 weeks)
Number of subjects: 880

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 880

Group type: COMPARATOR
Intervention: Breast-feeding (regardless of Methergin use)
Number of subjects: 880
Study: 3042354

Group type: EXPERIMENTAL
Intervention: urapidil 60 mg twice daily (adjustable to 30 mg, 60 mg, or 90 mg based on blood pressure response)
Number of subjects: 295

Group type: COMPARATOR
Intervention: captopril 25 mg twice daily (adjustable to 12.5 mg, 25 mg, or 50 mg based on blood pressure response)
Number of subjects: 295
Study: 29220114

Group type: EXPERIMENTAL
Intervention: Treat-and-extend (TAE) regimen with aflibercept
Number of subjects: 41

Group type: COMPARATOR
Intervention: Every-other-month (2M) regimen with aflibercept
Number of subjects: 41
Study: 28918112

Group type: EXPERIMENTAL
Intervention: Pegged glenoid component
Number of subjects: 46

Group type: COMPARATOR
Intervention: Keeled glenoid component
Number of subjects: 46
Study: 25553110

Group type: EXPERIMENTAL
Intervention: PEG-IFN therapy
Number of subjects: 140
Study: 24458902

Group type: EXPERIMENTAL
Intervention: Visual training program (experimental group)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Control group (without training)
Number of subjects: 26
Study: 21614492

Group type: EXPERIMENTAL
Intervention: Escitalopram
Number of subjects: 34
Study: 19216268

Group type: EXPERIMENTAL
Intervention: Titanium‐reinforced e‐PTFE membrane and allogeneic bone matrix
Number of subjects: 5

Group type: COMPARATOR
Intervention: Titanium‐reinforced e‐PTFE membrane and autogenous bone chips
Number of subjects: 5
Study: 16584354

Group type: COMPARATOR
Intervention: Enamel matrix derivative (EMD)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Antibiotics (250 mg metronidazole and 375 mg amoxicillin three times a day for 7 days)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 14620495

Group type: EXPERIMENTAL
Intervention: Intervention households received information about CVD and regular visits by social workers who measured cooking fats and salt and counselled cooks on the goals of intervention.
Number of subjects: 403

Group type: COMPARATOR
Intervention: Control group (not specified in detail in the abstract).
Number of subjects: 403
Study: 10896648

Group type: EXPERIMENTAL
Intervention: Diet-induced weight loss
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: Exercise-induced weight loss
Number of subjects: 52

Group type: COMPARATOR
Intervention: Exercise without weight loss
Number of subjects: 52

Group type: COMPARATOR
Intervention: Control
Number of subjects: 52
Study: 8810683

Group type: COMPARATOR
Intervention: Hydroxychloroquine
Number of subjects: 227

Group type: COMPARATOR
Intervention: Sulphasalazine
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: EULAR response criteria
Number of subjects: 227

Group type: EXPERIMENTAL
Intervention: ACR and WHO/ILAR response criteria
Number of subjects: 227
Study: 1426505

Group type: EXPERIMENTAL
Intervention: gemeprost
Number of subjects: 34

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 34

Group type: COMPARATOR
Intervention: parous control group (no gemeprost)
Number of subjects: 34
Study: 3914368

Group type: EXPERIMENTAL
Intervention: Desoximetasone ointment 0.25%
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluocinonide ointment 0.05%
Number of subjects: 0
Study: 30869644

Group type: EXPERIMENTAL
Intervention: App-based treatment program (Tät app) for SUI, 3-month duration focusing on pelvic floor muscle training (PFMT)
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: App-based treatment program (Tät app) for SUI
Number of subjects: 15
Study: 29574600

Group type: EXPERIMENTAL
Intervention: Endovascular treatment with near complete or complete recanalization (TICI grades 2b and 3)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Futile recanalization group
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Multivariate analysis predictors of futile recanalization
Number of subjects: 130
Study: 26947217

Group type: EXPERIMENTAL
Intervention: Aspirin use
Number of subjects: 1962
Study: 25486269

Group type: EXPERIMENTAL
Intervention: Dopaminergic medication (various types)
Number of subjects: 1741

Group type: EXPERIMENTAL
Intervention: Levodopa equivalent daily dose
Number of subjects: 1741
Study: 22562505

Group type: EXPERIMENTAL
Intervention: CCTV training combined with delivery instructions
Number of subjects: 122

Group type: COMPARATOR
Intervention: Delivery instructions only (Control)
Number of subjects: 122
Study: 20542811

Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 5543

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 5543
Study: 18717174

Group type: EXPERIMENTAL
Intervention: Molloplast B
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: GC Reline Soft
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Silagum Comfort
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Mollosil Plus
Number of subjects: 33
Study: 15687147

Group type: EXPERIMENTAL
Intervention: 10% resection of the femoral head‐neck junction
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 30% resection of the femoral head‐neck junction
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: 50% resection of the femoral head‐neck junction
Number of subjects: 15

Group type: COMPARATOR
Intervention: Contralateral femoral neck (control)
Number of subjects: 15
Study: 11481167

Group type: EXPERIMENTAL
Intervention: Clozapine
Number of subjects: 273

Group type: COMPARATOR
Intervention: Risperidone
Number of subjects: 273
Study: 9496247

Group type: EXPERIMENTAL
Intervention: Subcutaneous glucagon-like peptide-1(7-36)amide (GLP-1) at a dosage of 0.5 nmol/kg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Subcutaneous glucagon-like peptide-1(7-36)amide (GLP-1)
Number of subjects: 12
Study: 7827007

Group type: EXPERIMENTAL
Intervention: Ca-enriched lupin milk
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lupin flour bread
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Composite meals with lupin flour
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lupin-protein isolate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Lupin-milk base
Number of subjects: 0

Group type: COMPARATOR
Intervention: Soya-bean-milk base
Number of subjects: 0
Study: 2917311

Group type: EXPERIMENTAL
Intervention: Tamoxifen in combination with standard cytotoxic chemotherapy (doxorubicin, cis‐diamminedichloroplatinum)
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard cytotoxic chemotherapy (doxorubicin, cis‐diamminedichloroplatinum)
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Cytosol steroid receptor determinations
Number of subjects: 100
Study: 29621938

Group type: EXPERIMENTAL
Intervention: Strategy instruction on the Rey Osterrieth Complex Figure (ROCF)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Standard format of the Rey Osterrieth Complex Figure (ROCF)
Number of subjects: 98

Group type: EXPERIMENTAL
Intervention: Both groups (strategy instruction and standard format)
Number of subjects: 98
Study: 27734257

Group type: EXPERIMENTAL
Intervention: rhPTH(1-84)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 124
Study: 27053235

Group type: EXPERIMENTAL
Intervention: 6.5 mg/kg ATG (Thymoglobulin)
Number of subjects: 58

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 58
Study: 24713613

Group type: EXPERIMENTAL
Intervention: Sulpiride (high dose selective DA D2/3-receptor antagonist)
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control (no intervention mentioned)
Number of subjects: 78
Study: 23279492

Group type: EXPERIMENTAL
Intervention: Betamethasone (0.5 mg/kg) administered at 55 days post-ovulation
Number of subjects: 6

Group type: COMPARATOR
Intervention: Saline solution administered at 55 days post-ovulation (Control Group)
Number of subjects: 6
Study: 19852302

Group type: EXPERIMENTAL
Intervention: Runmushu Oral Liquid (RMS) combined with Hialid eye drops
Number of subjects: 72

Group type: COMPARATOR
Intervention: Hialid eye drops alone
Number of subjects: 72
Study: 17252006

Group type: EXPERIMENTAL
Intervention: Intravenous iron supplementation with subcutaneous epoetin beta 30,000 IU once weekly for 16 weeks
Number of subjects: 67

Group type: COMPARATOR
Intervention: Subcutaneous epoetin beta 30,000 IU once weekly for 16 weeks without intravenous iron
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: Intravenous iron supplementation with subcutaneous epoetin beta
Number of subjects: 67
Study: 15470311

Group type: EXPERIMENTAL
Intervention: Treadmill running
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Elliptical trainer
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: Stair-climber
Number of subjects: 22

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 22
Study: 11235144

Group type: EXPERIMENTAL
Intervention: LHRH agonist with flutamide (n = 5)
Number of subjects: 9

Group type: COMPARATOR
Intervention: LHRH agonist mono-therapy (n = 4)
Number of subjects: 9
Study: 9648044

Group type: EXPERIMENTAL
Intervention: Stimulant use as prescribed (Ritalin)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Stimulant use (Ritalin)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Stimulant storage policies in schools
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: School policies regarding prescription drugs
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: School policies regarding medication carrying
Number of subjects: 161
Study: 7990468

Group type: EXPERIMENTAL
Intervention: Moderate to severe problem drinking
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Mild problem drinking
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Problem drinking defined by CAGE Questionnaire and other indicators
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Social anxiety
Number of subjects: 369

Group type: EXPERIMENTAL
Intervention: Parental drinking
Number of subjects: 369
Study: 2537561

Group type: EXPERIMENTAL
Intervention: Enalapril 20 mg once daily
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg twice daily
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Enalapril (overall group)
Number of subjects: 142
Study: 31928949

Group type: EXPERIMENTAL
Intervention: Subanesthetic ketamine (0.5 mg/kg)
Number of subjects: 29

Group type: COMPARATOR
Intervention: Placebo saline infusion
Number of subjects: 29
Study: 29450737

Group type: EXPERIMENTAL
Intervention: Daily oral hygiene intervals (12 and 24 hours)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Extended oral hygiene intervals (48 and 72 hours)
Number of subjects: 52
Study: 28194525

Group type: EXPERIMENTAL
Intervention: SoluMatrix diclofenac 35 mg TID
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: SoluMatrix diclofenac 35 mg BID
Number of subjects: 305

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 305

Group type: EXPERIMENTAL
Intervention: SoluMatrix diclofenac 35 mg TID and BID
Number of subjects: 305
Study: 26496111

Group type: EXPERIMENTAL
Intervention: Transfusion of red blood cells (RBC) of varying storage ages
Number of subjects: 125
Study: 23291926

Group type: EXPERIMENTAL
Intervention: Vaginal cone therapy
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control group (HRT only)
Number of subjects: 22
Study: 21073974

Group type: EXPERIMENTAL
Intervention: Autologous HCT
Number of subjects: 30

Group type: COMPARATOR
Intervention: Allogeneic HCT
Number of subjects: 30
Study: 19339099

Group type: EXPERIMENTAL
Intervention: Group A (no anchors)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Group B (with mini fibre-reinforced composite anchors)
Number of subjects: 45

Group type: COMPARATOR
Intervention: Group C (resin composite buildups)
Number of subjects: 45